Key terms
About EIGR
Eiger BioPharmaceuticals, Inc. operates as a biopharmaceutical company, which focuses on the development of innovative therapies for rare metabolic diseases. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest EIGR news
Apr 12
8:31am ET
Two option delistings on April 12th
Apr 04
11:03am ET
Biotech Alert: Searches spiking for these stocks today
Apr 03
5:03pm ET
Eiger BioPharmaceuticals: Bankruptcy, Delisting, and Board Resignation
Apr 03
10:52am ET
Biotech Alert: Searches spiking for these stocks today
Apr 01
11:16am ET
Eiger BioPharmaceuticals files for voluntary Chapter 11 protection
Apr 01
10:53am ET
Eiger BioPharmaceuticals sinks following report of Chapter 11 filing
Apr 01
10:23am ET
Eiger BioPharmaceuticals sinks 35% to $3.26 after filing Chapter 11 bankruptcy
Apr 01
10:13am ET
Eiger BioPharmaceuticals trading resumes
Apr 01
10:12am ET
Eiger BioPharmaceuticals files for Chapter 11 bankruptcy, Bloomberg reports
Apr 01
10:08am ET
Eiger BioPharmaceuticals trading halted, volatility trading pause
Mar 11
4:12pm ET
Christine Murray Resigns from Eiger Biopharmaceuticals Board
Mar 04
9:43am ET
Eiger BioPharmaceuticals trading resumes
Mar 04
9:38am ET
Eiger BioPharmaceuticals trading halted, volatility trading pause
Feb 20
7:15am ET
Celcuity appoints Mayer as Chief Commercial Officer
Jan 25
4:47am ET
Eiger BioPharmaceuticals CCO Eldon Mayer III Resigns
Jan 18
6:00pm ET
Eiger BioPharmaceuticals, AnGes get Zokinvy marketing approval in Japan
No recent press releases are available for EIGR
EIGR Financials
Key terms
Ad Feedback
EIGR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
EIGR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range